ClinicalTrials.gg
Active, not recruitingNCT05774665Updated Jul 1, 2026

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

A Phase 2 interventional study of Omega 3 and Placebo in Treatment Resistant Depression, Inflammation and Overweight, sponsored by Massachusetts General Hospital. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Depressive Disorder, Treatment-Resistant by Massachusetts General Hospital — 2 open to participants now, 3 under way, none of them phase 3. Depressive Disorder, Treatment-Resistant · Massachusetts General Hospital.

Started
2025
the only one that year
Phase 2
5 of 11
none open now
Registered
9th of 11
by date

Among the 11 studies in Depressive Disorder, Treatment-Resistant by Massachusetts General Hospital, this one is the only one that started in 2025, is one of 5 in phase 2, and was the 9th registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

2 of the 11 studies in Depressive Disorder, Treatment-Resistant by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Depressive Disorder, Treatment-Resistant by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the impact of omega-3 fatty acids on the production of anti-inflammatory effects and clinical improvement in people with depression who have not responded well to standard antidepressant treatment. The main questions it seeks to answer are:

  1. Do omega-3 fatty acids added to ineffective antidepressant treatment increase production of compounds that reduce inflammation?
  2. Is the increase in these anti-inflammatory compounds associated with a stronger antidepressant effect?

Participants taking antidepressants that have not worked completely will be assigned at random for a 12-week period to one of the following:

  1. an omega-3 preparation
  2. an inactive placebo

During the course of the study, blood tests will be obtained for compounds associated with inflammation, and questionnaires to measure clinical improvement in depressive symptoms will be administered.

Read the detailed description

This R33 application builds directly on a previous collaborative R01 (NCT00517036) and UG3 (NCT02553915) grants. The investigators will carry out a 12-week, randomized placebo-controlled, double-masked, augmentation trial of 4 g/day eicosapentaenoic acid (EPA)-enriched omega-3 treatment in adults with major depressive disorder (MDD), an inadequate response to antidepressants (treatment-resistant depression [TRD]), body mass index (BMI) >25 kg/m2 and ≤ 40 kg/m2, and inflammation (high sensitivity C reactive protein [hs-CRP] ≥ 3 mg/L and ≤ 10 mg/L). It is hypothesized that 4 g/day of EPA-enriched omega-3 will: 1) Significantly increase plasma 18-hydroxy eicosapentaeoic acid [18-HEPE] concentrations compared to placebo (primary biological endpoint); 2) produce significantly greater increases in plasma 18-HEPE concentration since baseline for sustained MADRS responders (those with at least 50% reduction since baseline in MADRS scores at both treatment week 8 and week 12) than for (a) unsustained/non-responders to EPA-enriched n-3 as well as (b) placebo-supplemented sustained responders (secondary biological endpoint).

03

Conditions studied

  • Treatment Resistant Depression
  • Inflammation
  • Overweight

Keywords

  • omega-3
  • fatty acid
  • major depressive disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 to 65 years
  • Patients with treatment-resistant MDD who have not responded to at least 2 and no more than 5 antidepressant trials of at least 8 weeks duration during the current episode and have been on a current stable antidepressant regiment for at least 4 weeks. The diagnosis of MDD will be confirmed using the MINI and the historical failure to respond to antidepressant therapy will be documented using the Antidepressant Treatment Response Questionnaire (ATRQ), with failure to respond defined as less than 50% improvement by subject history.
  • hs-CRP ≥ 3 mg/L and ≤ 10 mg/L
  • >25 kg/m2 and ≤ 40 kg/m2
  • 17-item Hamilton Depression Rating Scale (HAM-D) score ≥15, and \<25% decrease in score between screen and baseline

Exclusion criteria

Exclusion Criteria:

Diagnostic Exclusions:

  • Meeting lifetime criteria for: a neurocognitive disorder, psychotic disorder, bipolar disorder, obsessive compulsive disorder, bulimia nervosa, or anorexia nervosa in the 3 months prior to the screening; any substance use disorder (except for nicotine or caffeine use disorder).
  • Patients who, in the investigator's judgment, pose a current, serious suicidal or homicidal risk
  • Presence of a serious or unstable medical illness, including insulin-dependent diabetes mellitus or bleeding disorder which, in the investigator's opinion, could compromise response to treatment, participant safety, or interpretation of study results.
  • Currently breastfeeding, pregnant women, or women of childbearing ability, who do NOT agree to use a study approved method of (described in the MOP) for the duration of the study.
  • Currently or within 90 days of screen participating in another clinical trial (excluding large natural cohort trials such as 'All of Us').

Treatment and Concomitant Medication Exclusions:

  • Failure to respond during the course of the current major depressive episode to >5 adequate antidepressant trials
  • Current use of antipsychotic medications or lithium
  • Having received ketamine therapy within 90 days of the screening visit
  • Patients who have initiated psychotherapy ≤ 90 days prior to screening.Having received electroconvulsive therapy during the current depressive episode or within 6 months of the screening visit
  • Concomitant use of any psychotropic agents within 2 weeks of the baseline visit, except for the ongoing antidepressant, prescription hypnotics, diphenhydramine, or a stable daily dose of a benzodiazepine.
  • Concomitant medications that might confound the biomarker findings within 1 week of the baseline visit and during the trial, including: regular (i.e. more than three times per week) ingestion of non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase (COX)-2 inhibitors; any use of oral , , interferon, chemotherapy, or anticoagulants.

Omega-3 Exclusions:

  • A history of severe sensitivity to soy products, fish products, or PUFA supplements
  • Patients who had taken supplements enriched with n-3 fatty acids within 60 days of the screening visit or who, at baseline, were consuming a diet containing > 3 g/day of n-3 fatty acids, or who consume > 2 meals of fatty fish per week.
  • Having taken a supplement of ≥1 g/day of n-3 fatty acids for ≥6 weeks during the current major depressive episode
  • Patients who have had either a poor response or intolerable side effects from n-3s in the past.
  • Patients with the following conditions: - Patients with the following conditions: history of atrial fibrillation or atrial flutter, left ventricle hypertrophy, stroke, cardiovascular disease (including coronary artery disease, heart failure, and moderate or severe valve disease or prior valve procedure), uncontrolled hypertension, Crohn's disease, Irritable Bowel Syndrome-diarrhea type, history of gastric bypass surgery, history of cholecystectomy, recent/current history of bulimia with purging, use of prokinetic medications that affect GI transit time, and small intestinal bacterial overgrowth (SIBO)
  • Sustained atrial fibrillation or atrial flutter of greater than 30 seconds detected by Holter monitor between V1 (screen) and V2 (baseline)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Omega-3

    Omega-3 fatty acid (ProEPA Xtra) capsules containing a total of 4 g/day of eicosapentaenoic acid (EPA), administered for 12 weeks.

    Drug: Omega 3

  • Placebo comparator
    Placebo

    Placebo capsules containing soybean oil (about 54% omega-6 and 6% omega-3, but no EPA or docosahexaenoic acid (DHA)), and matched to the ProEPA Xtra capsules in terms of appearance, odor, and taste.

    Other: Placebo

Interventions

  • DrugOmega-3 fatty acidStudies of Omega-3 fatty acidOmega-3 fatty acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Omega-3 fatty acid enriched for eicosapentaenoic acid (EPA)

    Also known as: EPA

  • OtherPlacebo

    Placebo consisting of soybean oil (about 54% omega-6 and 6% omega-3, but no EPA or docosahexaenoic acid (DHA)).

06

What researchers measure

Primary outcomes

  1. 18-HEPE (18-hydroxy eicosapentaeoic acid) Change

    Evaluate change in plasma 18-HEPE (18-hydroxy eicosapentaeoic acid) levels associated with 12 weeks of 4 g/day EPA-enriched n-3 treatment vs placebo.

    Time frame: 12 weeks

Secondary outcomes

  1. 18-HEPE (18-hydroxy eicosapentaeoic acid) Change in Treatment Responders

    To evaluate changes in plasma 18-HEPE (18-hydroxy eicosapentaeoic acid) level in relation to sustained clinical response status on the MADRS measure of depression severity.

    Time frame: 12 weeks

07

Study locations

3 sites
08

References and documents

Publications

  • Mischoulon D, Dunlop BW, Kinkead B, Schettler PJ, Lamon-Fava S, Rakofsky JJ, Nierenberg AA, Clain AJ, Mletzko Crowe T, Wong A, Felger JC, Sangermano L, Ziegler TR, Cusin C, Fisher LB, Fava M, Rapaport MH. Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial. J Clin Psychiatry. 2022 Aug 22;83(5):21m14074. doi: 10.4088/JCP.21m14074. PubMed 36005883 ↗

Individual participant data

Plan to share: Yes — Data will be stored password-protected in REDCap. Following publication, data will be available to external researchers upon request for replication or secondary analysis. Subject confidentiality will be protected per HIPAA policies. Internal and external requests will be handled by the PI to ensure equitable access, fairness and safeguards. After reviewing a proposal from an external investigator, PI will approve requests with appropriate experimental design, scientific merit and IRB approval and recommend revisions if necessary. Database searches are completed by the study statistician following PI approval, and reports will be provided to investigators. Information can be printed directly from database or exported in spreadsheets in various formats. Format will be controlled by the study statistician. Distribution of data is controlled and de-identified as much as possible.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Following publication of main study findings.

Access criteria: Interested investigators should contact the study team to inquire about data availability.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Mar 2027, 26 months after the start.

Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2023
First posted
Mar 20, 2023
StartActual
Jan 30, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05774665
Responsible party
David Mischoulon, MD, PhD (Director, Depression Clinical and Research Program, Massachusetts General Hospital) — Principal investigator
First posted
Mar 20, 2023
Start date
Jan 30, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

Mark H Rapaport, MD
principal investigator · University of Utah

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omega-3 fatty acid

Start the discussion